v3.26.1
Consolidated Statements of Operations and Comprehensive Income (Loss)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2025
CNY (¥)
¥ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
CNY (¥)
¥ / shares
shares
Dec. 31, 2023
CNY (¥)
¥ / shares
shares
Net revenues ¥ 116,362 $ 16,639 ¥ 186,356 ¥ 211,651
Cost of revenues (92,493) (13,227) (95,061) (94,143)
Gross profit 23,869 3,412 91,295 117,508
Sales and marketing expenses (43,918) (6,280) (41,269) (40,743)
General and administrative expenses (31,006) (4,434) (22,575) (23,592)
Research and development expenses (18,013) (2,576) (12,794) (11,901)
Reversal of (provision for) credit losses (1,438) (206) 1,782 3,714
Total operating expenses (94,375) (13,496) (74,856) (72,522)
Operating income (loss) (70,506) (10,084) 16,439 44,986
Other income (expenses):        
Interest income 96 14 231 312
Interest expense (3,400) (486) (4,043) (4,423)
Unrealized gains on short-term investments 127 18 209
Unrealized foreign exchange gain (loss) (312) (45) 679
Government subsidy 2,252 322 733 2,653
Other expenses (income) (130) (19) 146 234
Total other expenses, net (1,367) (196) (2,045) (1,224)
Income (loss) before income taxes (71,873) (10,280) 14,394 43,762
Income tax expenses (11,095) (1,587) (924) (6,253)
Net income (loss) (82,968) (11,867) 13,470 37,509
Net (income) loss attributable to noncontrolling interests 13,184 1,885 (2,159) (6,052)
Net income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders (69,784) (9,982) 11,311 31,457
Comprehensive income (loss)        
Net income (loss) (82,968) (11,867) 13,470 37,509
Net (income) loss attributable to noncontrolling interests 13,184 1,885 (2,159) (6,052)
Other comprehensive income (loss)        
Foreign currency translation adjustment (1,929) (275) 3
Total comprehensive income (loss) (84,897) (12,142) 13,473 37,509
Total comprehensive (income) loss attributable to non-controlling interest 13,184 1,885 (2,159) (6,052)
Total comprehensive income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders ¥ (71,713) $ (10,257) ¥ 11,314 ¥ 31,457
Weighted average shares outstanding used in calculating basic and diluted earnings per share:        
Ordinary shares – basic (in Shares) 47,349,869 47,349,869 45,666,376 45,666,376
Ordinary shares – diluted (in Shares) 47,349,869 47,349,869 45,666,376 45,666,376
Class A Ordinary shares        
Earnings (loss) per share:        
Basic – ordinary shares (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (1.47) $ (0.21) ¥ 0.25 ¥ 0.69
Diluted – ordinary shares (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (1.47) $ (0.21) ¥ 0.25 ¥ 0.69
Weighted average shares outstanding used in calculating basic and diluted earnings per share:        
Ordinary shares – basic (in Shares) [1] 7,349,869 7,349,869 5,666,376 5,666,376
Ordinary shares – diluted (in Shares) [1] 7,349,869 7,349,869 5,666,376 5,666,376
Class B Ordinary shares        
Earnings (loss) per share:        
Basic – ordinary shares (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (1.47) $ (0.21) ¥ 0.25 ¥ 0.69
Diluted – ordinary shares (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (1.47) $ (0.21) ¥ 0.25 ¥ 0.69
Weighted average shares outstanding used in calculating basic and diluted earnings per share:        
Ordinary shares – basic (in Shares) [1] 40,000,000 40,000,000 40,000,000 40,000,000
Ordinary shares – diluted (in Shares) [1] 40,000,000 40,000,000 40,000,000 40,000,000
[1] As of December 31, 2025, share reclassification was retroactively restated with effective date of March 24, 2026.